drugset / Trial / NCT00083460
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the combination.
Timeline
- Start
- 2001-12
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1 mg/m2 | — |
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Comparator | Thalidomide | Other / unclassified | 50 mg | — |
| Comparator | Thalidomide | Other / unclassified | 100 mg | — |
| Comparator | Thalidomide | Other / unclassified | 150 mg | — |
| Comparator | Thalidomide | Other / unclassified | 200 mg | — |
| Comparator | Dexamethasone | Small molecule | 20 mg | — |